Amneal surges on earnings beat, returns to profitability
Generic drugmaker raises 2026 guidance after specialty segment drives 38% growth
Amneal Pharmaceuticals delivered a stronger-than-expected fourth quarter, beating analyst estimates by a wide margin and returning the company to profitability for the first time since going private in 2018. The shares jumped in pre-market trading as the generic drugmaker raised its 2026 guidance and showcased the growing contribution of its specialty pharmaceuticals business.
The Bridgewater, New Jersey-based company reported adjusted earnings per share of $0.21 for the quarter ending December 31, 2025, surpassing the consensus estimate of $0.14 by 52 percent. Revenue reached $814 million, exceeding analyst projections of $774 million and marking a 12 percent increase from the same period a year earlier. The strong quarter helped Amneal achieve full-year 2025 profitability of $72 million, a dramatic turnaround from a $117 million loss in 2024.
"We delivered another quarter of strong execution across our diversified portfolio," said Chirag and Chintu Patel, co-chief executives of Amneal, in a statement accompanying the results. "Our Specialty segment continues to gain momentum, led by CREXONT, which has achieved impressive market penetration since launch."
The specialty pharmaceuticals business emerged as the primary growth driver, with revenue increasing 38 percent compared to the prior year. Much of that growth came from CREXONT, Amneal's Parkinson's disease treatment, which received FDA approval in August 2024 and launched commercially the following month. Within four months of launch, CREXONT had captured 1 percent of the market, and the company now projects the treatment could eventually generate peak annual sales of $300 million to $500 million.
The AvKARE segment, which focuses on generic pharmaceuticals and over-the-counter products, also demonstrated resilience with 24 percent revenue growth. The diversified performance marks Amneal's sixth consecutive year of consistent execution, according to company executives.
Buoyed by the strong results, Amneal raised its guidance for fiscal 2026. The company now projects revenue of $3.05 billion to $3.15 billion, up from previous expectations. Adjusted EBITDA is forecast to reach $720 million to $760 million, representing 5 percent to 10 percent year-over-year growth. Most significantly, management increased adjusted EPS guidance to $0.93 to $1.03, a range that represents 12 percent to 24 percent growth compared to the prior year.
The earnings beat and guidance raise come at a pivotal moment for Amneal, which was added to the S&P SmallCap 600 Index in January 2026. The inclusion typically brings increased visibility and institutional investment, potentially supporting the stock's 70 percent gain over the past 12 months.
Analysts have taken note of the transformation. Amneal currently carries a consensus rating of "Moderate Buy" or "Buy" from Wall Street firms, with five analysts covering the stock split between three Strong Buy and two Buy ratings, according to MarketBeat data. The average price target stands at $15.20, suggesting approximately 5 percent upside from current levels. Short interest has decreased by 16.44 percent in recent weeks, indicating improving investor sentiment.
The company's transition from pure generic manufacturer to a diversified specialty pharmaceutical player appears to be bearing fruit. While generic drugs historically faced intense pricing pressure and thin margins, specialty treatments like CREXONT offer higher margins and longer patent protection. Amneal's goal of achieving 50 percent formulary coverage for CREXONT in 2025 was surpassed early, with the drug now included in major national formularies including the Veterans Administration, UnitedHealthcare, and CVS Health.
Looking ahead, investors will be watching for progress on the Phase 4 ELEVATE-PD study for CREXONT, which has already shown substantial improvements in "Good On" time for Parkinson's patients. The company projects total specialty segment revenues could reach approximately $500 million by 2027, providing additional visibility on the earnings trajectory.
Despite the strong performance, Amneal faces challenges common to the pharmaceutical industry, including potential competition from generic versions of its products and regulatory scrutiny. The company's beta of 1.35 indicates higher volatility than the broader market, reflecting these risks.
For now, though, the fourth-quarter results suggest Amneal's strategy is working. The combination of a profitable year, raised guidance, and strengthening specialty pipeline has positioned the company for what analysts project could be another year of double-digit growth in 2026.